Silence Therapeutics (SLN) Investor Presentation - Slideshow

Company Vision and Strategy - Silence Therapeutics aims to transform lives by silencing diseases with precision medicines, leveraging its mRNAi GOLD™ platform through a hybrid business model[11] - The company's partnered pipeline has a potential of ~$7.5 billion in milestones plus royalties[13] - Silence Therapeutics' proforma cash balance is approximately $110 million, expected to fund the company into Q2 2024[13] - The company's market capitalization is approximately $367 million as of September 9, 2022[14] Clinical Program Highlights - SLN360 (Cardiovascular Disease) showed up to 98% Lp(a) reduction in a Phase 1 study after a single dose[55] - SLN124 (Hematological Disorders) showed an average hepcidin increase of up to ~4-fold in a Phase 1 study after a single dose[55] - Approximately 10% of the global population has >90 mg/dL Lp(a), indicating a 2-3x increased heart attack risk[58] - SLN124 increased average hepcidin up to ~4-fold and reduced serum iron ~50% after a single dose in healthy volunteers[101] Partnerships - AstraZeneca deal includes up to $4 billion in potential milestones plus tiered royalties for 10 targets[43] - Mallinckrodt collaboration includes up to $2 billion in potential milestones plus royalties for 3 targets[43] - Hansoh collaboration includes up to $1.3 billion in potential milestones plus royalties for undisclosed targets[43]